CU6 9.43% $5.57 clarity pharmaceuticals ltd

Ann: First participant treated in the last dose escalation cohort, page-18

  1. 23,040 Posts.
    lightbulb Created with Sketch. 1425
    "One of the patients in cohort 3 will be soon receiving his second dose of 67Cu-SAR-bisPSMA at 12GBq under EAP"

    From the announcement on the 30th November

    I wonder if we'll get to see the outcome for him
 
watchlist Created with Sketch. Add CU6 (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.